

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

75-311

CHEMISTRY REVIEW(S)

MAY 20 1998

38. Chemistry comments to be Provided to the Applicant

ANDA: 75-311

APPLICANT: Teva Pharmaceuticals USA

DRUG PRODUCT Famotidine Tablets USP, 20 mg and 40 mg

The deficiencies presented below represent FACSIMILE DEFICIENCIES.

A. Deficiencies:


1. In reference to Starch apparently lists under the same COA two different batch Nos. and different quantities of bags shipped. The test results for each are presented in two parallel columns. Batch WR5042 is included in both COAs, one covers 560 bags and the second 380 bags. Apparently Teva's COA (p. 1817) has a typo and should read: Vendor batch: WR5016. Please clarify.
2. The application provides for alternate testing procedures. Please acknowledge that the USP procedure remains the regulatory method and, results obtained thereof, are to rule in the event of a dispute.
3. In reference to your stability studies, we are cognizant that the stability studies may be performed in any of the three available sites under the "domain" of Teva Pharmaceutical Industries Ltd. Please include in your stability summaries reports the site in which the study is being conducted.

B. In addition to responding to the deficiencies presented above, please note and acknowledge the following comments in your response:

1. You included in the FDA 356h form / in error, please revise.
2. You stated that samples of the drug product are available upon request from the FDA. You should have included the drug substance as well (p. 2533).

3. Some of your certificates of analysis for HDPE bottles as presented are apparently a bottle design conformance report.

Sincerely yours,



Frank O. Holcombe, Jr., Ph.D.
Director

Division of Chemistry II
Office of Generic Drugs
Center for Drug Evaluation and Research

1. CHEMISTRY REVIEW NO. 5

2. ANDA # 75-311

3. NAME AND ADDRESS OF APPLICANT

Teva Pharmaceuticals USA
Attn: Philip Erickson
1090 Horsham Road
North Wales, PA 19454-1090

4. BASIS OF SUBMISSION

Reference Listed drug product: Pepcid^R by Merck. US Patent #4283408 expires 10/15/00, after pediatric exclusivity, 4/15/01.

The proposed drug product contains the same active ingredients and has same strength, dosages form, route of administration, indications and usage as the listed drug.

5. SUPPLEMENT(s)

N/A

6. PROPRIETARY NAME

NA

7. NONPROPRIETARY NAME

Famotidine

8. SUPPLEMENT(s) PROVIDE(s) FOR:

N/A

9. AMENDMENTS AND OTHER DATES:

Original submission: 12-9-97
Telephone amendment: 2-5-98
FDA Acceptable for filing 2-13-98
Fax Deficiency letter: 5/20/98
Amendment Response: 6/19/98
Tentative Approval: 10/15/98
Minor Amendment to TA: 8/8/00
Minor Deficiency: 11/16/00
Amendment: 11/22/00
Telephone Amendment: 11/7/00
Amendment: 12/7/00
Tentative Approval (2nd): 1/31/01
Minor amendment: 2/20/01

10. PHARMACOLOGICAL CATEGORY
Antiulcer

11. Rx or OTC
Rx

12. RELATED IND/NDA/DMF(s)

...manufacturer Famotidine

For other Type III DMFs see 356h form

13. DOSAGE FORM
Tablet

14. POTENCY
20 mg and 40 mg

15. CHEMICAL NAME AND STRUCTURE
Listed in labeling insert.

16. RECORDS AND REPORTS
N/A

17. COMMENTS

This application was reviewed in accordance with OGD policy. Original reviewer was A. Croituro. No re-review was performed, a TA was issued in 1998. Since this time, there were issues regarding the famotidine drug substance purchased by . A minor letter was issued to the applicant regarding these chemistry issues. The firm responded satisfactorily by revising the impurities specifications as requested. A 2nd TA was issued on 1/31/01. The firm submitted a minor amendment to the TA on 2/2/01. All CMC issues are acceptable. Application is ready for full approval. Process impurity : is not monitored in the drug product.

18. CONCLUSIONS AND RECOMMENDATIONS

The application is now a full approval as of 4/15/01.

19. REVIEWER:
Karen A. Bernard, Ph.D.

DATE COMPLETED:
3-14-01

cc:

Endorsements:

f

k

1-14-01

175

Chemistry Review - Approvable